With the COVID-19 having made a severe impact on various industries in the United States, it is challenging to predict precisely how the pharmaceutical and healthcare market will be performing in a short time. However, there is no doubt that the pharmaceutical and healthcare sector has been affected seriously. With the economic slowdown setting in due to the pandemic, the US pharmaceutical and healthcare industry is expected to decelerate in the short term.
The US pharmaceutical industry is a highly globalized industry dominated by multinational companies that engage in significant business activity in many countries and whose products are distributed and marketed worldwide. Over the past few decades, the industry has undergone dramatic structural changes, with the rise of the biotechnology sector, substantial growth in demand driven by demographics and substitution away from other therapeutic modalities such as surgery, and increased competition from globally active generic manufacturers.
The publisher presents an in-depth analysis of the Pharmaceutical and Healthcare Industry of United States in its research report Pharmaceutical and Healthcare Industry in the US - Forecast and Analysis 2021.
A detailed forecast of the US pharmaceutical and healthcare industry by segments completes this comprehensive analysis.
The US pharmaceutical industry is a highly globalized industry dominated by multinational companies that engage in significant business activity in many countries and whose products are distributed and marketed worldwide. Over the past few decades, the industry has undergone dramatic structural changes, with the rise of the biotechnology sector, substantial growth in demand driven by demographics and substitution away from other therapeutic modalities such as surgery, and increased competition from globally active generic manufacturers.
The publisher presents an in-depth analysis of the Pharmaceutical and Healthcare Industry of United States in its research report Pharmaceutical and Healthcare Industry in the US - Forecast and Analysis 2021.
The report covers the following data:
- An in-depth coverage of the pharmaceutical and healthcare industry in the US by sectors along with an analysis of how the COVID-19 pandemic is effecting the industry.
- We analyze the segments of prescription drugs, generic drugs, OTC medicines, and also analyze the landscape for clinical trials in the US.
- A SWOT analysis of the US pharmaceutical and healthcare industry.
- A Porter's Five Forces Strategic Analysis of the US pharmaceutical and healthcare Industry is included that looks at the bargaining power of buyers and suppliers, competitive rivalry in the industry, and the threat of new entrants and industry substitution.
- We take an up-close view of the regulatory framework governing the US pharmaceutical and healthcare industry.
- Competition in the industry, along with an in-depth analysis of the major players like AstraZeneca, Eli Lilly, Glaxo Smith Kline, and many others are included.
A detailed forecast of the US pharmaceutical and healthcare industry by segments completes this comprehensive analysis.
Table of Contents
A. Executive SummaryB. Industry DefinitionH. Import/Export of PharmaceuticalsL. Glossary of TermsM. Research MethodologyN. Disclaimer
C. Pharmaceutical & Healthcare Industry in the US
D. US Pharmaceutical & Healthcare Industry: SWOT Analysis
E. US Pharmaceutical Industry: Porter’s Five Forces Strategy Analysis
F. Chronic Medical Conditions in the US
G. Regulatory Framework of the Industry
I. Competition in the Industry
J. Forecast: Pharmaceutical & Healthcare Industry in the US
K. Pharmaceutical & Healthcare Industry: Major Players
List of Figures
List of Tables
Companies Mentioned
- AbbVie
- Amgen
- Apotex
- AstraZeneca
- Bristol Myers Squibb
- Eli Lilly and Company
- Gilead Sciences
- GlaxoSmithKline
- Johnson & Johnson
- Merck & Co.
- Novartis
- Pfizer
- Sanofi SA
- Teva Pharmaceutical Industries Ltd.